FIELD: medicine.
SUBSTANCE: invention relates to the use of a compound A, which is a compound of the formula (I) or its pharmaceutically acceptable salt, in a combination with a compound B, which is febuxostat, for the production of a drug for the treatment of gout or hyperuricemia, while a dose of the compound A is 10 mg, a dose of febuxostat is 80 mg, and the weight ratio of the compound A and febuxostat is 1:8.
EFFECT: treatment of gout and hyperuricemia with a combination of a compound A and a compound B, showing a good therapeutic effect and insignificant side reaction.
7 cl, 4 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS AND COMPOSITIONS FOR TREATING HYPERURICEMIA AND METABOLIC DISORDERS ASSOCIATED WITH HYPERURICEMIA | 2012 |
|
RU2603050C2 |
| THERAPEUTIC OR PREVENTIVE AGENT FOR TUMOUR LYSIS SYNDROME | 2013 |
|
RU2627591C2 |
| METHODS FOR PRESERVING RENAL FUNCTION WITH USING XANTHINE OXIDOREDUCTASE | 2007 |
|
RU2508099C2 |
| METHODS AND SETS FOR PREDICTING RISK OF INFUSION RESPONSES AND ANTIBODY-MEDIATED LOSS OF RESPONSE IN THERAPY WITH PEGYLATED URICASE BY MONITORING URIC ACID CONTENT IN BLOOD SERUM | 2010 |
|
RU2535038C2 |
| INTRACELLULAR ATP INCREASING COMBINATION | 2016 |
|
RU2728722C2 |
| SODIUM SALT OF THE URIC ACID TRANSPORTER INHIBITOR AND ITS CRYSTALLINE FORM | 2016 |
|
RU2719484C2 |
| NOVEL SALT AND MEDICAL APPLICATION | 2012 |
|
RU2609011C2 |
| USING IL-1 ANTAGONISTS FOR TREATING GOUT | 2007 |
|
RU2450824C2 |
| COMPOUNDS AND METHODS FOR URIC ACID REDUCTION | 2009 |
|
RU2501555C2 |
| COMPOUNDS AND METHODS FOR URIC ACID REDUCTION | 2009 |
|
RU2501554C2 |
